Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10 percent (IGIV, 10 percent) for the Treatment of Mild to Moderate Alzheimer's Disease.

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10 percent (IGIV, 10 percent) for the Treatment of Mild to Moderate Alzheimer's Disease.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GAP
  • Sponsors Baxalta

    • Most Recent Events

    • 05 Apr 2017 Results assessing safety and efficacy of Immune-globulin in ITT population and subgroups, published in the Neurology
    • 16 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
    • 16 Jul 2013 Positive data from cognition and biomarker tests presented at the Alzheimer's Association International Conference 2013 (AAIC 2013), according to a Baxter International media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top